Chemical Proteomic Discovery of Isotype-Selective Covalent Inhibitors of the RNA Methyltransferase NSUN2
Overview
Authors
Affiliations
5-Methylcytosine (m C) is an RNA modification prevalent on tRNAs, where it can protect tRNAs from endonucleolytic cleavage to maintain protein synthesis. The NSUN family (NSUN1-7 in humans) of RNA methyltransferases are capable of installing the methyl group onto the C position of cytosines in RNA. NSUNs are implicated in a wide range of (patho)physiological processes, but selective and cell-active inhibitors of these enzymes are lacking. Here, we use cysteine-directed activity-based protein profiling (ABPP) to discover azetidine acrylamides that act as stereoselective covalent inhibitors of human NSUN2. Despite targeting a conserved catalytic cysteine in the NSUN family, the NSUN2 inhibitors show negligible cross-reactivity with other human NSUNs and exhibit good proteome-wide selectivity. We verify that the azetidine acrylamides inhibit the catalytic activity of recombinant NSUN2, but not NSUN6, and demonstrate that these compounds stereoselectively disrupt NSUN2-tRNA interactions in cancer cells, leading to a global reduction in tRNA m C content. Our findings thus highlight the potential to create isotype-selective and cell-active inhibitors of NSUN2 with covalent chemistry targeting a conserved catalytic cysteine.
Nidoieva Z, Sabin M, Dewald T, Weldert A, Hoba S, Helm M Commun Chem. 2025; 8(1):32.
PMID: 39900960 PMC: 11790956. DOI: 10.1038/s42004-025-01439-9.
Wu H, Chen S, Li X, Li Y, Shi H, Qing Y MedComm (2020). 2025; 6(1):e70042.
PMID: 39802639 PMC: 11718328. DOI: 10.1002/mco2.70042.
Wang R, Ding L, Lin Y, Luo W, Xu Z, Li W Int J Biol Sci. 2024; 20(15):6241-6254.
PMID: 39664561 PMC: 11628344. DOI: 10.7150/ijbs.101337.
RNA Modifications in Pathogenic Viruses: Existence, Mechanism, and Impacts.
Zou Y, Guo Z, Ge X, Qiu Y Microorganisms. 2024; 12(11).
PMID: 39597761 PMC: 11596894. DOI: 10.3390/microorganisms12112373.
Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid.
Wang Q, Du T, Zhang Z, Zhang Q, Zhang J, Li W Acta Pharm Sin B. 2024; 14(10):4431-4442.
PMID: 39525590 PMC: 11544177. DOI: 10.1016/j.apsb.2024.07.005.